Arkolith/Insider Trading/TPTX/Form 4

Countouriotis Athena

President & CEO, DirectorTurning Point Therapeutics, Inc. (TPTX) · full profile →Form 4 · filed Aug 17, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 17, 2022Disposed to issuer(D)111K$76.00$8.4M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 17, 2022Disposed to issuer(D)102K——0
Aug 17, 2022Disposed to issuer(D)225K——0
Aug 17, 2022Disposed to issuer(D)68K——0
Aug 17, 2022Disposed to issuer(D)325K——0
Aug 17, 2022Disposed to issuer(D)173K——0
Aug 17, 2022Disposed to issuer(D)990K——0
Aug 17, 2022Disposed to issuer(D)156K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-046258) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML